{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:17:38Z","timestamp":1762273058884,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002909","name":"Comisi\u00f3n Nacional de Energ\u00eda At\u00f3mica, Gobierno de Argentina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT0041"],"award-info":[{"award-number":["PICT0041"]}],"id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PIP0082"],"award-info":[{"award-number":["PIP0082"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02092-6","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T05:02:35Z","timestamp":1681362155000},"page":"2353-2365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-4549","authenticated-orcid":false,"given":"M.","family":"Perona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. L.","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Thomasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Villaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Oglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rosemblit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Grissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Campos-Haedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Dagrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cremaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. A.","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Juvenal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"2092_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2014) Cronin K SEER Cancer Statistics Review, 1975\u20132011, National Cancer Institute, Bethesda, Md, USA, 2013, based on November 2013 SEER data submission, posted to the SEER web site http:\/\/seer.cancer.gov\/csr\/1975_2011\/. Accessed 25 July 2022"},{"issue":"7","key":"2092_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1445-2197.2004.03062.x","volume":"74","author":"MJ Veness","year":"2004","unstructured":"Veness MJ, Porter GS, Morgan GJ (2004) Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 74(7):559\u2013562. https:\/\/doi.org\/10.1111\/j.1445-2197.2004.03062.x","journal-title":"ANZ J Surg"},{"issue":"11","key":"2092_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"Smallridge RC, Ain KB, Asaetal SL (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11):1104\u20131139. https:\/\/doi.org\/10.1089\/thy.2012.0302","journal-title":"Thyroid"},{"issue":"11","key":"2092_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/BF03345066","volume":"23","author":"B Busnardo","year":"2000","unstructured":"Busnardo B, Daniele O, Pelizzo MR, Mazzarotto R, Nacamulli D, Devido D, Mian C, Girelli ME (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 23(11):755\u2013761. https:\/\/doi.org\/10.1007\/BF03345066","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2092_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1","volume":"91","author":"PI Haigh","year":"2001","unstructured":"Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91(12):2335\u20132342","journal-title":"Cancer"},{"key":"2092_CR6","doi-asserted-by":"publisher","first-page":"764281","DOI":"10.1155\/2014\/764281","volume":"2014","author":"MJ Stavas","year":"2014","unstructured":"Stavas MJ, Shinohara ET, Attia A, Ning MS, Friedman JM, Cmelak AJ (2014) Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma. J Thyroid Res 2014:764281. https:\/\/doi.org\/10.1155\/2014\/764281","journal-title":"J Thyroid Res"},{"issue":"1","key":"2092_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13044-020-00091-w","volume":"13","author":"S De Leo","year":"2020","unstructured":"De Leo S, Trevisan M, Fugazzola L (2020) Recent advances in the management of anaplastic thyroid cancer. Thyroid Res 13(1):17. https:\/\/doi.org\/10.1186\/s13044-020-00091-w","journal-title":"Thyroid Res"},{"issue":"2","key":"2092_CR8","first-page":"323","volume":"6","author":"PM Harari","year":"2000","unstructured":"Harari PM, Huang SM (2000) Modulation of molecular targets to enhance radiation. Clin Cancer Res 6(2):323\u2013325","journal-title":"Clin Cancer Res"},{"issue":"32","key":"2092_CR9","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"AA Lane","year":"2009","unstructured":"Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32):5459\u20135468. https:\/\/doi.org\/10.1200\/JCO.2009.22.1291","journal-title":"J Clin Oncol"},{"issue":"4","key":"2092_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jcb.22185","volume":"107","author":"PA Marks","year":"2009","unstructured":"Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107(4):600\u2013608. https:\/\/doi.org\/10.1002\/jcb.22185","journal-title":"J Cell Biochem"},{"issue":"21","key":"2092_CR11","doi-asserted-by":"publisher","first-page":"8198","DOI":"10.3390\/ijms21218198","volume":"21","author":"K Ranganna","year":"2020","unstructured":"Ranganna K, Selvam C, Shivachar A, Yousefipour Z (2020) Histone deacetylase inhibitors as multitarget-directed epi-drugs in blocking PI3k oncogenic signaling: a polypharmacology approach. Int J Mol Sci 21(21):8198. https:\/\/doi.org\/10.3390\/ijms21218198","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2092_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","volume":"101","author":"PN Munster","year":"2009","unstructured":"Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Clin Trial Br J Cancer 101(7):1044\u20131050. https:\/\/doi.org\/10.1038\/sj.bjc.6605293","journal-title":"Clin Trial Br J Cancer"},{"key":"2092_CR13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/bjc.2013.21","volume":"108","author":"B Groselj","year":"2013","unstructured":"Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108:748\u2013754. https:\/\/doi.org\/10.1038\/bjc.2013.21","journal-title":"Br J Cancer"},{"issue":"13","key":"2092_CR14","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/ijms20133259","volume":"20","author":"S Moertl","year":"2019","unstructured":"Moertl S, Payer S, Kell R, Winkler K, Anastasov N, Atkinson MJ (2019) Comparison of radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in pancreatic cancer cells. Int J Mol Sci 20(13):3259. https:\/\/doi.org\/10.3390\/ijms20133259","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2092_CR15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00415-009-5156-9","volume":"256","author":"MS van Breemen","year":"2009","unstructured":"van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256(9):1519\u20131526. https:\/\/doi.org\/10.1007\/s00415-009-5156-9","journal-title":"J Neurol"},{"issue":"12","key":"2092_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/jhg.2017.91","volume":"62","author":"MM Zhu","year":"2017","unstructured":"Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL (2017) The pharmacogenomics of valproic acid. J Hum Genet 62(12):1009\u20131014. https:\/\/doi.org\/10.1038\/jhg.2017.91","journal-title":"J Hum Genet"},{"issue":"24","key":"2092_CR17","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969\u20136978. https:\/\/doi.org\/10.1093\/emboj\/20.24.6969","journal-title":"EMBO J"},{"key":"2092_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/med.20027","volume":"25","author":"RA Blaheta","year":"2005","unstructured":"Blaheta RA, Michaelis M, Driever PH, Cinatl JJ (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25:383\u2013397. https:\/\/doi.org\/10.1002\/med.20027","journal-title":"Med Res Rev"},{"key":"2092_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/00001813-199609000-00008","volume":"7","author":"JJ Cinatl","year":"1996","unstructured":"Cinatl JJ, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Kornhuber B (1996) Antitumor activity of sodium valproate in cultures of human neuroblastomacells. Anticancer Drugs 7:766\u2013773. https:\/\/doi.org\/10.1097\/00001813-199609000-00008","journal-title":"Anticancer Drugs"},{"key":"2092_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1055\/s-2008-1043809","volume":"211","author":"PH Driever","year":"1999","unstructured":"Driever PH, Kn\u00fcpfer MM, Cinatl J, Wolff JEA (1999) Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 211:323\u2013328. https:\/\/doi.org\/10.1055\/s-2008-1043809","journal-title":"Klin Padiatr"},{"key":"2092_CR21","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.2174\/138161207782360528","volume":"13","author":"M Michaelis","year":"2007","unstructured":"Michaelis M, Doerr HW, Cinatl J (2007) Valproic acid as anti-cancer drug. Current Pharmaceut Des 13:3378\u20133393","journal-title":"Current Pharmaceut Des"},{"issue":"3","key":"2092_CR22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1210\/jc.2004-1355","volume":"90","author":"MG Catalano","year":"2005","unstructured":"Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G (2005) Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90(3):1383\u20131389. https:\/\/doi.org\/10.1210\/jc.2004-1355","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2092_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1210\/jc.2003-031407","volume":"89","author":"N Fortunati","year":"2004","unstructured":"Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G (2004) Valproic acid induces the expression of the Na+\/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89(2):1006\u20131009. https:\/\/doi.org\/10.1210\/jc.2003-031407","journal-title":"J Clin Endocrinol Metab"},{"issue":"28","key":"2092_CR24","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1038\/sj.onc.1209417","volume":"25","author":"TC Karagiannis","year":"2006","unstructured":"Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25(28):3885\u20133893. https:\/\/doi.org\/10.1038\/sj.onc.1209417","journal-title":"Oncogene"},{"issue":"3","key":"2092_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3892\/or.2015.4089","volume":"34","author":"N Makita","year":"2015","unstructured":"Makita N, Ninomiya I, Tsukada T, Okamoto K, Harada S, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Katsunobu O, Hisatoshi N, Tomoharu M, Hidehiro T, Hiroyuki T, Sachio F, Tetsuo O (2015) Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells. Oncol Rep 34(3):1185\u20131192. https:\/\/doi.org\/10.3892\/or.2015.4089","journal-title":"Oncol Rep"},{"issue":"3","key":"2092_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1039\/c5tx00476d","volume":"5","author":"Y Luo","year":"2016","unstructured":"Luo Y, Wang H, Zhao XP, Dong X, Zhang FM, Guo G, Guo WXW, Powell SN, Feng ZH (2016) Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway. Toxicol Res (Cam) 5(3):859\u2013870. https:\/\/doi.org\/10.1039\/c5tx00476d","journal-title":"Toxicol Res (Cam)"},{"key":"2092_CR27","doi-asserted-by":"publisher","first-page":"65504","DOI":"10.1863\/oncotarget.11798","volume":"7","author":"B Van Oorschot","year":"2016","unstructured":"Van Oorschot B, Granata G, Franco S, Cate R, Rodermond HM, Todaro M, Medema JP, Franken NAP (2016) Targeting DNA double strand break repair with hyperthermia and DNA-PKCS inhibition to enhance the effect of radiation treatment. Oncotarget 7:65504\u201365513. https:\/\/doi.org\/10.1863\/oncotarget.11798","journal-title":"Oncotarget"},{"key":"2092_CR28","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","volume":"14","author":"P Chinnaiyan","year":"2008","unstructured":"Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410\u20135415. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0643","journal-title":"Clin Cancer Res"},{"key":"2092_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.mce.2018.08.007","volume":"478","author":"M Perona","year":"2018","unstructured":"Perona M, Thomasz L, Rossich L, Rodriguez C, Pisarev MA, Rosemblit C, Cremaschi GA, Dagrosa MA, Juvenal GJ (2018) Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid. Mol Cell Endocrinol 478:141\u2013150. https:\/\/doi.org\/10.1016\/j.mce.2018.08.007","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2092_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","volume":"86","author":"CA Barker","year":"2013","unstructured":"Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86(3):504\u2013509. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.02.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2092_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","volume":"92","author":"AV Krauze","year":"2015","unstructured":"Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K (2015) A phase 2 study of concurrent radiation therapy, Temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 92(5):986\u2013992. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.038","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2092_CR32","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/sj.bjc.6600361","volume":"86","author":"J Tennvall","year":"2002","unstructured":"Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL, Wallin G (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86(12):1848\u20131853. https:\/\/doi.org\/10.1038\/sj.bjc.6600361","journal-title":"Br J Cancer"},{"key":"2092_CR33","doi-asserted-by":"publisher","first-page":"479364","DOI":"10.1155\/2010\/479364","volume":"2010","author":"S Chateauvieux","year":"2010","unstructured":"Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010:479364. https:\/\/doi.org\/10.1155\/2010\/479364","journal-title":"J Biomed Biotechnol"},{"key":"2092_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1507\/endocrj.k08e-016","volume":"56","author":"H Noguchi","year":"2009","unstructured":"Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, Yokoi T, Noguchi S (2009) Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 56:245\u2013249. https:\/\/doi.org\/10.1507\/endocrj.k08e-016","journal-title":"Endocr J"},{"key":"2092_CR35","doi-asserted-by":"publisher","first-page":"2930414","DOI":"10.1155\/2016\/2930414","volume":"2016","author":"MG Catalano","year":"2016","unstructured":"Catalano MG, Pugliese M, Gallo M, Brignardello E, Milla P, Orlandi F, Limone PP, Arvat E, Boccuzzi G, Piovesan A (2016) Valproic acid, a histone deacetylase inhibitor, in combination with paclitaxel for anaplastic thyroid cancer: results of a multicenter randomized controlled phase II\/III trial. Int J Endocrinol 2016:2930414. https:\/\/doi.org\/10.1155\/2016\/2930414","journal-title":"Int J Endocrinol"},{"issue":"1","key":"2092_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/cen.13154","volume":"86","author":"N Nilubol","year":"2016","unstructured":"Nilubol N, Merkel R, Yang L, Patel D, Reynolds JC, Sadowski SM, Neychev V, Kebebew E (2016) A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. Clin Endocrinol (Oxf) 86(1):128\u2013133. https:\/\/doi.org\/10.1111\/cen.13154","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2092_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206\u2013222. https:\/\/doi.org\/10.1016\/j.ctrv.2007.11.003","journal-title":"Cancer Treat Rev"},{"key":"2092_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrc1560","volume":"5","author":"JM Brown","year":"2005","unstructured":"Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231\u2013237. https:\/\/doi.org\/10.1038\/nrc1560","journal-title":"Nat Rev Cancer"},{"key":"2092_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4161\/cbt.4.7.1922","volume":"4","author":"TC Karagiannis","year":"2005","unstructured":"Karagiannis TC, Harikrishnan KN, El-Osta A (2005) The histone deacetylase inhibitor, trichostatin a, enhances radiation sensitivity and accumulation of gammaH2A.X. Cancer Biol Ther 4:787\u2013793. https:\/\/doi.org\/10.4161\/cbt.4.7.1922","journal-title":"Cancer Biol Ther"},{"issue":"30","key":"2092_CR40","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2217\/fon-2020-0385","volume":"16","author":"E Shirbhate","year":"2020","unstructured":"Shirbhate E, Patel P, Patel VK, Veerasamy R, Sharma PC, Rajak H (2020) The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment. Future Oncol 16(30):2457\u20132469. https:\/\/doi.org\/10.2217\/fon-2020-0385","journal-title":"Future Oncol"},{"issue":"4","key":"2092_CR41","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3892\/ijo_00000728","volume":"37","author":"T Kawano","year":"2010","unstructured":"Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T, Ida H, Agata N, Yamada H (2010) Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int J Oncol 37(4):787\u2013795. https:\/\/doi.org\/10.3892\/ijo_00000728","journal-title":"Int J Oncol"},{"key":"2092_CR42","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.18632\/oncotarget.3692","volume":"6","author":"HY Chiou","year":"2015","unstructured":"Chiou HY, Lai WK, Huang LC, Huang SM, Chueh SH, Ma HI, Hueng DY (2015) Valproic acid promotes radiosensitization in meningioma stem-like cells. Oncotarget 6:9959\u20139969. https:\/\/doi.org\/10.18632\/oncotarget.3692","journal-title":"Oncotarget"},{"issue":"5","key":"2092_CR43","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/carcin\/23.5.687","volume":"23","author":"SP Jackson","year":"2002","unstructured":"Jackson SP (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23(5):687\u2013696. https:\/\/doi.org\/10.1093\/carcin\/23.5.687","journal-title":"Carcinogenesis"},{"key":"2092_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijrobp.2003.09.028","volume":"58","author":"PL Olive","year":"2004","unstructured":"Olive PL, Ban\u00e1th JP (2004) Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 58:331\u2013335. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.09.028","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"2092_CR45","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-10-0523","volume":"16","author":"CE Redon","year":"2010","unstructured":"Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y (2010) Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 16(18):4532\u20134542. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0523","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2092_CR46","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1073\/pnas.0830918100","volume":"100","author":"K Rothkamm","year":"2003","unstructured":"Rothkamm K, L\u00f6brich M (2003) Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA 100(9):5057\u20135062. https:\/\/doi.org\/10.1073\/pnas.0830918100","journal-title":"Proc Natl Acad Sci USA"},{"key":"2092_CR47","doi-asserted-by":"publisher","first-page":"19579","DOI":"10.1074\/jbc.C300117200","volume":"278","author":"IM Ward","year":"2003","unstructured":"Ward IM, Minn K, Jorda KG, Chen J (2003) Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J Biol Chem 278:19579\u201319582. https:\/\/doi.org\/10.1074\/jbc.C300117200","journal-title":"J Biol Chem"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02092-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T01:09:12Z","timestamp":1696640952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02092-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02092-6","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"17 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In this article no studies involving human participants or animals were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Formal consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}